{
  "asset": "TECVAYLI (teclistamab)",
  "query_terms": [
    "TECVAYLI (teclistamab)",
    "teclistamab",
    "TECVAYLI"
  ],
  "returned_unique": 29,
  "kept": 10,
  "studies": [
    {
      "nct_id": "NCT06285318",
      "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
      "overall_status": "RECRUITING",
      "phase": null,
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma (RRMM)"
      ],
      "lead_sponsor": "Janssen-Cilag Ltd.",
      "collaborators": [],
      "interventions": [
        "Teclistamab",
        "Talquetamab"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
    },
    {
      "nct_id": "NCT06208150",
      "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Talquetamab",
        "Pomalidomide",
        "Teclistamab",
        "Elotuzumab",
        "Dexamethasone",
        "Bortezomib"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
    },
    {
      "nct_id": "NCT06251076",
      "title": "Outpatient-based Teclistamab Step-up Dosing in Patients With Relapsed/Refractory Multiple Myeloma: Process Development in Academic and Community Centres, and Evaluating Impact on Caregiver Burden",
      "overall_status": "RECRUITING",
      "phase": null,
      "conditions": [
        "Multiple Myeloma",
        "Relapsed Cancer",
        "Refractory Cancer"
      ],
      "lead_sponsor": "University Health Network, Toronto",
      "collaborators": [
        "Janssen Inc."
      ],
      "interventions": [
        "Teclistamab",
        "Tocilizumab"
      ],
      "last_update": "2025-12-10",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06251076"
    },
    {
      "nct_id": "NCT07110844",
      "title": "A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Amyloid Light-chain Amyloidosis"
      ],
      "lead_sponsor": "Suzanne Lentzsch, MD",
      "collaborators": [
        "Janssen Pharmaceuticals"
      ],
      "interventions": [
        "Teclistamab",
        "Daratumumab and Hyaluronidase-fihj"
      ],
      "last_update": "2025-11-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07110844"
    },
    {
      "nct_id": "NCT05083169",
      "title": "A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Daratumumab",
        "Pomalidomide",
        "Dexamethasone",
        "Bortezomib",
        "Teclistamab"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05083169"
    },
    {
      "nct_id": "NCT04722146",
      "title": "A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Teclistamab",
        "Daratumumab",
        "Pomalidomide",
        "Lenalidomide",
        "Bortezomib",
        "Nirogacestat"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04722146"
    },
    {
      "nct_id": "NCT06425991",
      "title": "A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants With Relapsed/Refractory Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Relapsed or Refractory Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Teclistamab"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06425991"
    },
    {
      "nct_id": "NCT06577025",
      "title": "A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Cilta-cel",
        "Talquetamab",
        "Daratumumab",
        "Teclistamab",
        "Bortezomib",
        "Lenalidomide",
        "Dexamethasone",
        "Cyclophosphamide",
        "Fludarabine"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06577025"
    },
    {
      "nct_id": "NCT05972135",
      "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "SCRI Development Innovations, LLC",
      "collaborators": [
        "Johnson & Johnson"
      ],
      "interventions": [
        "Teclistamab",
        "Talquetamab",
        "Tocilizumab"
      ],
      "last_update": "2025-10-29",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
    },
    {
      "nct_id": "NCT06477783",
      "title": "Prospective Observational Study on the Clinical Efficacy of Teclistamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium",
      "overall_status": "RECRUITING",
      "phase": null,
      "conditions": [
        "Multiple Myeloma",
        "Hematologic Diseases"
      ],
      "lead_sponsor": "Universitaire Ziekenhuizen KU Leuven",
      "collaborators": [
        "Janssen Pharmaceutica"
      ],
      "interventions": [
        "Teclistamab"
      ],
      "last_update": "2025-03-12",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06477783"
    }
  ]
}